Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EDESA BIOTECH, INC.

(EDSA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Edesa Biotech : to Present at the H.C. Wainwright Global Investment Conference

09/09/2021 | 08:42am EST

TORONTO, ON / ACCESSWIRE / September 9, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr. Par Nijhawan, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually from September 13 to 15, 2021. Dr. Nijhawan is expected to provide an overview of Edesa's business and corporate strategy.

An on-demand corporate presentation will be accessible to conference attendees starting on Monday, September 13, 2021 at 7:00 am ET. Dr. Nijhawan and Edesa senior management will also be available for one-on-one meetings. Attendees who are interested in meeting with the company should contact their H.C. Wainwright representative or Edesa directly via email at investors@edesabiotech.com.

More information about the 23rd Annual Global Investment Conference is available at the H.C. Wainwright conference website.

About Edesa Biotech, Inc.
Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. The company's two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy that we are developing as a treatment for Acute Respiratory Distress Syndrome (ARDS). ARDS is a life-threatening form of respiratory failure, and the leading cause of death among COVID-19 patients. Edesa is also developing an sPLA2 inhibitor, designated as EB01, as a topical treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. By targeting sPLA2 with enzyme inhibitors - at the inception of inflammation rather than after inflammation has occurred - Edesa believes that drugs based on this technology could provide a powerful anti-inflammatory therapeutic strategy for treating diverse inflammatory/allergic conditions. The company is based in Markham, Ontario, Canada, with a U.S. subsidiary located in Southern California. Sign up for news alerts. Connect with Edesa Biotech on Twitter and LinkedIn.

Edesa Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as 'anticipate,' 'believe,' 'plan,' 'estimate,' 'expect,' 'intend,' 'may,' 'will,' 'would,' 'could,' 'should,' 'might,' 'potential,' or 'continue' and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises, such as COVID-19. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.

CONTACT:
Gary Koppenjan
Edesa Biotech, Inc.
(805) 488-2800 ext. 150
investors@edesabiotech.com

SOURCE: Edesa Biotech



View source version on accesswire.com:
https://www.accesswire.com/663053/Edesa-Biotech-to-Present-at-the-HC-Wainwright-Global-Investment-Conference

Disclaimer

Edesa Biotech Inc. published this content on 09 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 September 2021 12:41:08 UTC.


ę Publicnow 2021
All news about EDESA BIOTECH, INC.
12/01EDESA BIOTECH : Marks Enrollment Milestone in Dermatitis Study
PU
11/22EDESA BIOTECH, INC. : Entry into a Material Definitive Agreement, Financial Statements and..
AQ
11/04Edesa Biotech Extends COVID-19 Clinical Study to Poland
PU
11/04Edesa Biotech, Inc. Announces Polish Regulators Approves Clinical Trial Application for..
CI
10/19EDESA BIOTECH : Says its COVID-19 Drug Candidate Reduces Mortality, Based on Phase 2 Study..
MT
10/19EDESA BIOTECH : Reports Favorable Mortality Reductions in COVID-19 Study
PU
10/19Edesa Biotech Reports Favorable Mortality Reductions in Covid-19 Study
CI
09/20Top Midday Gainers
MT
09/20Edesa Biotech Sees Positive Results From Study for Covid-19 Treatment
DJ
09/20Top Premarket Gainers
MT
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -15,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,86x
Yield 2021 -
Capitalization 75,9 M 75,9 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 3,10x
Nbr of Employees 12
Free-Float 71,3%
Chart EDESA BIOTECH, INC.
Duration : Period :
Edesa Biotech, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EDESA BIOTECH, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 5,71 $
Average target price 19,00 $
Spread / Average Target 233%
EPS Revisions
Managers and Directors
Pardeep Nijhawan Chief Executive Officer, Secretary & Director
Michael Brooks President
Kathi Niffenegger Chief Financial Officer
Sean A. MacDonald Chairman
Blair Gordon Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
EDESA BIOTECH, INC.34.82%76
GILEAD SCIENCES, INC.19.58%87 393
BIONTECH SE310.30%80 545
REGENERON PHARMACEUTICALS31.23%66 288
WUXI APPTEC CO., LTD.26.31%65 499
VERTEX PHARMACEUTICALS-13.49%51 982